Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | GFER | P55789 | 1/20 | 0.66 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.57 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | PLG | P00747 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7247695 | 1.00 | KMT2A (0.66) | KMT2AMEN1MAPTPSMD14PKM | |
| SCHEMBL20558928 | 0.91 | KMT2A (0.62) | KMT2AMEN1MAPTPSMD14PKM | |
| SCHEMBL20558930 | 0.91 | KMT2A (0.62) | KMT2AMEN1MAPTPSMD14PKM | |
| SCHEMBL6881330 | 0.85 | KMT2A (0.61) | KMT2AMEN1MAPTPSMD14PKM | |
| SCHEMBL6881328 | 0.85 | KMT2A (0.61) | KMT2AMEN1MAPTPSMD14PKM | |
| SCHEMBL6885160 | 0.81 | KMT2A (0.65) | KMT2AMEN1MAPTPSMD14PKM | |
| SCHEMBL6885161 | 0.81 | KMT2A (0.65) | KMT2AMEN1MAPTPSMD14PKM | |
| SCHEMBL7050939 | 0.81 | PTPN12 (0.62) | KMT2AMEN1MAPTPSMD14PKM | |
| SCHEMBL7050943 | 0.81 | PTPN12 (0.62) | KMT2AMEN1MAPTPSMD14PKM | |
| SCHEMBL6886576 | 0.81 | MEN1 (0.59) | KMT2AMEN1MAPTPSMD14PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | ANGELIKA ESSWEIN, WOLFGANG SCHAEFER, AND KONRAD HONOLD | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | NR1H4, NR1D1, NR1I2 | KMT2A 1995/4885MEN1 838/4885MAPT 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.